Evidence map›Paper›PMID 37343697›Full record

ArticleMolecular & cellular proteomics : MCP2023

Cross-Linking Mass Spectrometry Uncovers Interactions Between High-Density Lipoproteins and the SARS-CoV-2 Spike Glycoprotein.

Sean A Burnap, Ana Maria Ortega-Prieto, Jose M Jimenez-Guardeño, Hashim Ali, Kaloyan Takov, Matthew Fish, Manu Shankar-Hari, Mauro Giacca, Michael H Malim, Manuel Mayr

Open access · goldAbstract read
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. ApoD mediates age-associated increase in vulnerability to influenza virus infection.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Clinical Proteomics: A Promise Becoming Reality.Molecular & cellular proteomics : MCP · 2024
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Sean A BurnapDepartment of Chemistry, Physical and Theoretical Chemistry Laboratory, University of Oxford, Oxford, UK; The Kavli Institute for Nanoscience Discovery, Dorothy Crowfoot Hodgkin Building, University of Oxford, Oxford, UK; King's College London British Heart Foundation Centre, School of Cardiovascular Medicine and Sciences, London, UK. Electronic address: sean.burnap@chem.ox.ac.uk.
Ana Maria Ortega-PrietoDepartment of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK.
Jose M Jimenez-GuardeñoDepartment of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK.
Hashim AliKing's College London British Heart Foundation Centre, School of Cardiovascular Medicine and Sciences, London, UK; Division of Virology, Department of Pathology, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
Kaloyan TakovKing's College London British Heart Foundation Centre, School of Cardiovascular Medicine and Sciences, London, UK.
Matthew FishDepartment of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK; Department of Intensive Care Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Manu Shankar-HariCentre for Inflammation Research, Institute of Regeneration and Repair, University of Edinburgh, Edinburgh, UK; Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, UK.
Mauro GiaccaKing's College London British Heart Foundation Centre, School of Cardiovascular Medicine and Sciences, London, UK.
Michael H MalimDepartment of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK.
Manuel MayrKing's College London British Heart Foundation Centre, School of Cardiovascular Medicine and Sciences, London, UK. Electronic address: manuel.mayr@kcl.ac.uk.
King's College London · GBNHS Lothian · GB

Funding

British Heart Foundation CH/16/3/32406British Heart Foundation PG/20/10387British Heart Foundation RG/F/21/110053Wellcome TrustWellcome Trust 222433/Z/21/Z
6 · The paper itself

Abstract

High-density lipoprotein (HDL) levels are reduced in patients with coronavirus disease 2019 (COVID-19), and the extent of this reduction is associated with poor clinical outcomes. While lipoproteins are known to play a key role during the life cycle of the hepatitis C virus, their influence on coronavirus (CoV) infections is poorly understood. In this study, we utilize cross-linking mass spectrometry (XL-MS) to determine circulating protein interactors of the severe acute respiratory syndrome (SARS)-CoV-2 spike glycoprotein. XL-MS of plasma isolated from patients with COVID-19 uncovered HDL protein interaction networks, dominated by acute-phase serum amyloid proteins, whereby serum amyloid A2 was shown to bind to apolipoprotein (Apo) D. XL-MS on isolated HDL confirmed ApoD to interact with SARS-CoV-2 spike but not SARS-CoV-1 spike. Other direct interactions of SARS-CoV-2 spike upon HDL included ApoA1 and ApoC3. The interaction between ApoD and spike was further validated in cells using immunoprecipitation-MS, which uncovered a novel interaction between both ApoD and spike with membrane-associated progesterone receptor component 1. Mechanistically, XL-MS coupled with data-driven structural modeling determined that ApoD may interact within the receptor-binding domain of the spike. However, ApoD overexpression in multiple cell-based assays had no effect upon viral replication or infectivity. Thus, SARS-CoV-2 spike can bind to apolipoproteins on HDL, but these interactions do not appear to alter infectivity.

Indexed as

COVID-19HumansLipoproteins, HDLMass SpectrometryProtein BindingSARS-CoV-2Spike Glycoprotein, CoronavirusLipoproteins, HDLSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2ApoDHDLSARS-CoV-2spikeXL-MS

Identifiers

PMID37343697
PMCPMC10279469
OpenAlexW4381250113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.